CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.950
-0.130 (-3.19%)
At close: Dec 5, 2025, 4:00 PM EST
4.070
+0.120 (3.04%)
After-hours: Dec 5, 2025, 6:40 PM EST
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 6.50, with a low estimate of 5.00 and a high estimate of 10. The average target predicts an increase of 64.56% from the current stock price of 3.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 2 | 2 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $10 | Strong Buy | Maintains | $5 → $10 | +153.16% | Nov 11, 2025 |
| Barclays | Barclays | Buy Maintains $3.5 → $6 | Buy | Maintains | $3.5 → $6 | +51.90% | Oct 21, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $6 | Buy | Initiates | $6 | +51.90% | Sep 22, 2025 |
| Barclays | Barclays | Buy Initiates $3.5 | Buy | Initiates | $3.5 | -11.39% | Sep 17, 2025 |
| Oppenheimer | Oppenheimer | Buy Initiates $7 | Buy | Initiates | $7 | +77.22% | Jul 31, 2025 |
Financial Forecast
Revenue This Year
85.41M
from 138.10M
Decreased by -38.16%
Revenue Next Year
42.09M
from 85.41M
Decreased by -50.71%
EPS This Year
-0.01
from 0.38
EPS Next Year
-0.39
from -0.01
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 95.1M | 107.1M | ||||
| Avg | 85.4M | 42.1M | ||||
| Low | 77.9M | 3.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -31.2% | 25.4% | ||||
| Avg | -38.2% | -50.7% | ||||
| Low | -43.6% | -95.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 0.06 | -0.22 | ||||
| Avg | -0.01 | -0.39 | ||||
| Low | -0.06 | -0.53 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -83.3% | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.